Avelas Biosciences to Present at 28th Annual Roth Conference
SAN DIEGO, March 8, 2016 — Avelas Bioscienes, Inc., a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment, today announced that Carmine N. Stengone, president and chief executive officer, will present an overview of the company at the 28th Annual Roth Conference on Tuesday, March 15, 2016, at 12:20 p.m. PT at The Ritz Carlton, Laguna Nigel, California.
About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. The company’s lead candidate, AVB-620, is in a Phase 1b trial planned for enrollment of up to 39 breast cancer patients, assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. Avelas was founded by Avalon Ventures on technology from Nobel laureate Roger Y. Tsien, Ph.D.